BR112017017448A2 - métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho - Google Patents
métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olhoInfo
- Publication number
- BR112017017448A2 BR112017017448A2 BR112017017448A BR112017017448A BR112017017448A2 BR 112017017448 A2 BR112017017448 A2 BR 112017017448A2 BR 112017017448 A BR112017017448 A BR 112017017448A BR 112017017448 A BR112017017448 A BR 112017017448A BR 112017017448 A2 BR112017017448 A2 BR 112017017448A2
- Authority
- BR
- Brazil
- Prior art keywords
- eye
- methods
- treatment
- eye disorders
- compositions
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010013774 Dry eye Diseases 0.000 abstract 1
- 230000006589 gland dysfunction Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562119857P | 2015-02-24 | 2015-02-24 | |
| PCT/US2016/019207 WO2016138049A1 (en) | 2015-02-24 | 2016-02-23 | Methods and compositions for treating dry eye disease and other eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017017448A2 true BR112017017448A2 (pt) | 2018-04-03 |
Family
ID=56692824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017017448A BR112017017448A2 (pt) | 2015-02-24 | 2016-02-23 | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9597328B2 (https=) |
| EP (1) | EP3261620B1 (https=) |
| JP (1) | JP2018506570A (https=) |
| KR (1) | KR20170132725A (https=) |
| CN (1) | CN107427459A (https=) |
| AU (1) | AU2016222902A1 (https=) |
| BR (1) | BR112017017448A2 (https=) |
| CA (1) | CA2976120A1 (https=) |
| ES (1) | ES2936394T3 (https=) |
| MX (1) | MX2017010544A (https=) |
| RU (1) | RU2691412C2 (https=) |
| WO (1) | WO2016138049A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
| US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
| US8083787B2 (en) | 2005-07-18 | 2011-12-27 | Tearscience, Inc. | Method and apparatus for treating meibomian gland dysfunction |
| US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
| US20170232024A1 (en) | 2014-08-04 | 2017-08-17 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
| US11478437B2 (en) * | 2016-07-05 | 2022-10-25 | Jenivision Inc. | Formulations for hair growth |
| EP3624773A4 (en) * | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | OPHTHALMIC COMPOSITIONS AND METHOD OF USE |
| US11759472B2 (en) | 2017-11-21 | 2023-09-19 | Cs Pharmaceuticals Limited | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| IL274810B2 (en) * | 2017-11-21 | 2025-12-01 | Axerovision Inc | Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface |
| WO2019118928A1 (en) | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| JP6653037B2 (ja) * | 2018-03-30 | 2020-02-26 | 千寿製薬株式会社 | 水性液剤 |
| JP6621955B2 (ja) * | 2018-03-30 | 2019-12-18 | 千寿製薬株式会社 | 水性液剤 |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| CN111212642A (zh) * | 2018-08-29 | 2020-05-29 | 奥古根有限公司 | 眼用组合物及使用方法 |
| US12502377B2 (en) | 2019-04-04 | 2025-12-23 | Tarsus Pharmaceuticals, Inc. | Method of eradicating ticks that attach to humans using lotilaner formulations |
| MX2022007056A (es) * | 2019-12-10 | 2022-07-11 | Alcon Inc | Insertos oculares polimericos disolvibles con un polimero biodegradable. |
| WO2022031830A1 (en) * | 2020-08-04 | 2022-02-10 | Harrow Ip Llc | Antibacterial compositions and methods for fabricating thereof |
| WO2022109497A1 (en) * | 2020-11-23 | 2022-05-27 | Sight Sciences, Inc. | Formulations and methods for treating conditions of the eye |
| CN116710087A (zh) * | 2020-11-23 | 2023-09-05 | 美国商业眼科医疗器械公司 | 用于治疗眼部病症的制剂和方法 |
| EP4085891A1 (en) * | 2021-05-05 | 2022-11-09 | B. Braun Melsungen AG | Dexmedetomidine-solution in a low-density polyethylene container |
| CN115645356A (zh) * | 2022-11-21 | 2023-01-31 | 山东诺明康药物研究院有限公司 | 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用 |
| WO2025174723A1 (en) * | 2024-02-12 | 2025-08-21 | Selagine Inc. | Ophthalmic composition comprising cethromycin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK3412U (sk) * | 2002-07-01 | 2003-01-09 | Unimed Pharma Spol Sro | Očná inštalácia so zlepšenou stabilitou účinnej látky na báze brimomidínu |
| US20040088199A1 (en) * | 2002-10-31 | 2004-05-06 | Childress Allen B. | Method of forming a business rule |
| US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
| JP2007528897A (ja) * | 2004-03-12 | 2007-10-18 | メルビ ホールディングス， エルエルシー | 眼表面用の潤滑剤 |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| CN101352441A (zh) * | 2007-07-27 | 2009-01-28 | 肖正连 | 一种酒石酸溴莫尼定眼用即型凝胶 |
| US20120003296A1 (en) * | 2010-07-01 | 2012-01-05 | Shantha Totada R | New methods of treating dry eye syndrome |
| HUE038366T2 (hu) * | 2010-08-16 | 2018-10-29 | Allergan Inc | Módszer szabályozó T-sejtek alfa-2B adrenerg receptor agonistákkal való aktiválásához |
| US20120076738A1 (en) * | 2010-09-28 | 2012-03-29 | Michael Graeber | Combination treatment for dermatological conditions |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| US20120093876A1 (en) * | 2010-10-13 | 2012-04-19 | Aciex, Inc. | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions |
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
| EP2630952A1 (en) * | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
-
2016
- 2016-02-23 KR KR1020177023704A patent/KR20170132725A/ko not_active Withdrawn
- 2016-02-23 RU RU2017129247A patent/RU2691412C2/ru active
- 2016-02-23 AU AU2016222902A patent/AU2016222902A1/en not_active Abandoned
- 2016-02-23 CN CN201680011749.3A patent/CN107427459A/zh active Pending
- 2016-02-23 BR BR112017017448A patent/BR112017017448A2/pt not_active Application Discontinuation
- 2016-02-23 ES ES16756227T patent/ES2936394T3/es active Active
- 2016-02-23 WO PCT/US2016/019207 patent/WO2016138049A1/en not_active Ceased
- 2016-02-23 CA CA2976120A patent/CA2976120A1/en active Pending
- 2016-02-23 EP EP16756227.1A patent/EP3261620B1/en active Active
- 2016-02-23 US US15/051,654 patent/US9597328B2/en active Active
- 2016-02-23 MX MX2017010544A patent/MX2017010544A/es unknown
- 2016-02-23 JP JP2017545544A patent/JP2018506570A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3261620A4 (en) | 2018-10-31 |
| EP3261620B1 (en) | 2022-11-09 |
| RU2017129247A (ru) | 2019-03-25 |
| EP3261620A1 (en) | 2018-01-03 |
| RU2691412C2 (ru) | 2019-06-13 |
| CA2976120A1 (en) | 2016-09-01 |
| AU2016222902A1 (en) | 2017-08-31 |
| JP2018506570A (ja) | 2018-03-08 |
| RU2017129247A3 (https=) | 2019-03-25 |
| WO2016138049A1 (en) | 2016-09-01 |
| ES2936394T3 (es) | 2023-03-16 |
| US9597328B2 (en) | 2017-03-21 |
| US20160243116A1 (en) | 2016-08-25 |
| KR20170132725A (ko) | 2017-12-04 |
| MX2017010544A (es) | 2018-06-18 |
| CN107427459A (zh) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| MX378579B (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
| MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
| BR112017001093A2 (pt) | formulação aquosa compreendendo paracetamol e ibuprofeno | |
| MX2018016332A (es) | Quimioterapias de combinacion. | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| BR112019006216A2 (pt) | compostos de p2x3 e/ou p2x2/3 e métodos | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| MX382357B (es) | Métodos y composiciones para tratar infecciones fúngicas cutáneas. | |
| MX2020008275A (es) | Metodos para tratar trastornos mitocondriales. | |
| BR112019008516A2 (pt) | derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo | |
| BR112019006174A2 (pt) | proteina terapêutica | |
| MX2019000849A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| BR112017027285A2 (pt) | ?cocristal, composição farmacêutica e método para o tratamento de uma doença? | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |